matsupexole (KDT-3594) / Kissei - LARVOL DELTA

A Late Phase II Clinical Trial of KDT-3594 in Patients With Parkinson's Disease (clinicaltrials.gov) - P2 | N=150 | Active, not recruiting | Sponsor: Kissei Pharmaceutical Co., Ltd. | Recruiting ➔ Active, not recruiting

Enrollment closed • CNS Disorders • Movement Disorders • Parkinson's Disease

Matsupexole: A novel nonergot dopamine receptor agonist with sustained efficacy in a rat model of Parkinson's disease and limited off-target activity. (PubMed, Br J Pharmacol) - "Matsupexole is a promising future, potentially best-in-class dopamine receptor agonist for treating PD."

Journal • Preclinical • Cardiovascular • CNS Disorders • Heart Failure • Movement Disorders • Parkinson's Disease • Sleep Disorder

A Late Phase II Clinical Trial of KDT-3594 in Patients With Parkinson's Disease (clinicaltrials.gov) - P2 | N=150 | Recruiting | Sponsor: Kissei Pharmaceutical Co., Ltd.

Metastases • New P2 trial • CNS Disorders • Movement Disorders • Parkinson's Disease

A Clinical Study of KDT-3594 in Japanese Patients With Early Parkinson's Disease (clinicaltrials.gov) - P2 | N=7 | Completed | Sponsor: Kissei Pharmaceutical Co., Ltd. | Active, not recruiting ➔ Completed | Trial completion date: Mar 2022 ➔ Sep 2021 | Trial primary completion date: Mar 2022 ➔ Sep 2021

Trial completion • Trial completion date • Trial primary completion date • CNS Disorders • Movement Disorders • Parkinson's Disease

A Clinical Study of KDT-3594 in Japanese Patients With Early Parkinson's Disease (clinicaltrials.gov) - P2; N=6; Active, not recruiting; Sponsor: Kissei Pharmaceutical Co., Ltd.; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed • CNS Disorders • Movement Disorders • Parkinson's Disease

AffaMed Therapeutics Announces Approval for the Phase IIb Clinical Study of AM006 in China for the Treatment of Parkinson’s Disease (PRNewswire) - "AffaMed Therapeutics...today announced that China's National Medical Products Administration (NMPA) has approved the Clinical Trial Application (CTA) for a Phase IIb global clinical trial led by AffaMed to evaluate the safety and efficacy of AM006 in patients with early Parkinson's Disease (PD)...By 2030 however, China is expected to account for close to 50% of PD patients globally, illustrating the significant scale of treatment needs required to be met in the future."

New P2b trial • Non-US regulatory • CNS Disorders • Parkinson's Disease

A Clinical Study of KDT-3594 in Japanese Patients With Early Parkinson's Disease (clinicaltrials.gov) - P2; N=6; Recruiting; Sponsor: Kissei Pharmaceutical Co., Ltd.

Clinical • New P2 trial • CNS Disorders • Movement Disorders • Parkinson's Disease

A Clinical Study of KDT-3594 in Patients With Early Parkinson's Disease. (clinicaltrials.gov) - P2; N=74; Completed; Sponsor: Kissei Pharmaceutical Co., Ltd.; Active, not recruiting ➔ Completed; Trial completion date: Jun 2020 ➔ Feb 2020; Trial primary completion date: Jun 2020 ➔ Feb 2020

Clinical • Trial completion • Trial completion date • Trial primary completion date • CNS Disorders • Movement Disorders • Parkinson's Disease

CBC-funded Affamed merges with Everinsight, extends portfolio with Kissei PD candidate (Bioworld) - Subscription needed.

Licensing / partnership • CNS Disorders • Parkinson's Disease

A Clinical Study of KDT-3594 in Patients With Early Parkinson's Disease. (clinicaltrials.gov) - P2; N=100; Active, not recruiting; Sponsor: Kissei Pharmaceutical Co., Ltd.; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed

Clinical Study of KDT-3594 in Healthy Adult Males and Patients With Parkinson's Disease (clinicaltrials.gov) - P1; N=36; Completed; Sponsor: Kissei Pharmaceutical Co., Ltd.; Active, not recruiting ➔ Completed; Trial completion date: Jan 2019 ➔ Aug 2018; Trial primary completion date: Jan 2019 ➔ Aug 2018

Clinical • Trial completion • Trial completion date • Trial primary completion date

A Clinical Study of KDT-3594 in Patients With Early Parkinson's Disease. (clinicaltrials.gov) - P2; N=100; Recruiting; Sponsor: Kissei Pharmaceutical Co., Ltd.

Clinical • New P2 trial